Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2- resistant autologous acute myeloid leukaemia blasts

British Journal of Haematology

Volumn 101, Issue 1, 1998, Pages 150-157

  Vitale, Antonella ^a   Guarini, Anna ^a   Latagliata, Roberto ^a   Cignetti, Alessandro ^b   Foa, Robert ^a,b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Dipto Biotecnologie Cellulari ed E   (Italy)

Author keywords

AML; Cytokines; Cytotoxic activity; IL 12; IL 2

Indexed keywords

ANTILEUKEMIC AGENT; INTERLEUKIN 12; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0031957426     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00645.x     Document Type: Article

References (45)

1. Benyunes, M.C., Massumoto, C., York, A., Higuchi, C.M., Buckner, C.D., Thompson, J.A., Petersen, F.B. & Fefer, A. (1993) Interleukin-2 with or without lymphokine-activated killer cells as consolidalive immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Morrow Transplantation. 12. 159-163.
2. Bigda, J., Mysliwska, J., Dziadziuszko, R., Bigda, J., Mysliwski, A. & Hellmann, A. (1993) Interleukin-12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia. Leukemia and Lymphoma. 10, 121-125.
3. Bree, A.G., Schlerman, F.J., Kaviani, M.D., Hastings, R.C., Hitz, S.L. & Gloldman, S.J. (1994) Multiple effects on peripheral hematology following administration of recombinant interleukin-12 to non-human primates. Biochemical and Biophysical Research Communications. 204, 1150-1157.
4. Broder, S. & Waldmann, T.A. (1978) The suppressor network in cancer. New England Journal of Medicine, 299, 1281-1284.
5. Brunda, M.J. (1994) Interleukin-12. Journal of Leukocyte Biology, 55, 280-288.
6. Brunda, M.J., Luistro, L., Warrier, R.R., Wright, R.B., Hubbard, B.R., Murphy. M., Wolf. S.F. & Gately, M.K. (1993) Antitumor and antimetastatic activity of interleukin-12 against murine tumors. Journal of Experimental Medicine, 178, 1223-1230.
7. Caligiuri, M.A., Murray, C., Robertson, M.J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M.E., Klumpp, T.R., Soiffer, R.J., Smith, K.A. & Ritz, J. (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. Journal of Clinical Investigation, 91, 123-132.
8. Chan, S.H., Perussia, B., Gupta, J.W., Kobayashi, M., Pospisil, M., Young, H.A., Wolf, S.F., Young, D., Clark, S.C. & Trinchieri, G. (1991) Induction of Interferon γ production by natural killer cell stimulatory factor: characterization of the responders cells and synergy with other inducers. Journal of Experimental Medicine, 173, 869-879.
9. Chehimi, J., Valiante, N.M., d'Andrea, A., Rengaraju, M., Rosado, Z., Kobayashi, M., Perussia, A. & Gately, M.K. (1993) Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell mediated cytotoxicity against tumor-derived and virus infected cells. European Journal of Immunology, 23, 1826-1830.
10. Cignetti, A., Guarini, A., Carbone, A., Forni, M., Cronin, K., Forni, G., Gansbacher, B. & Foa, K. (1994) Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. Journal of the National Cancer Institute, 86, 785-791.
11. Fierro, M.T., Xin-Sheng, L., Lusso, P., Bonferroui, M., Matera, L., Cesano, A., Lista, P., Arione, R., Forni, G. & Foa, R. (1988) In vitro and in vivo susceptibility of human lcukemic cell to lymphokine activated killer activity. Leukemia, 2, 50-54.
12. Foa, R. (1995) Interleukin 2 in the management of acute leukaemia. British Journal of Haematology, 92, 1-8.
13. Foa, R., Fierro, M.T., Cesano, A., Guarini, A., Bonferroni, M., Raspadori, D., Miniero, R., Lauria, F. & Gavosto, F. (1991a) Defective lymphokine activated killer cell-generation and activity in acute leukemia patients with active disease. Blood. 78, 1041-1046.
14. Foa, R., Fierro, M.T., Tosti, S., Meloni, G., Gavosto, F. & Mandelli, F. (1990) Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leukemia and Lymphoma, 1, 113-117.
15. Foa, R., Meloni, G., Tosti, S., Novarino, A., Fenu, S., Gavosto, F. & Mandelli, F. (1991b) Treatment of acute leukaemia patients with recombinant interleukin-2; a pilot study. British Journal of Haematology, 77, 491-496.
16. Forni, G., Foa, R., Santoni, A. & Frati, L. (1994) Cytokine-induced Tumor Immunogenicity: from Ezogenous Molecules to Gene Therapy, Academic Press, Landon.
17. Gately, M.D., Desai, B.B., Wolitsky, A.G., Quinn, P.M., Dwyer, C.M., Podlaski, F.J., Familletti, P.C., Sinigaglia, F., Chizzonite, R., Gubler, U. & Stern, A.S. (1991) Regulation of human lymphocyte proliferation by a heterodimeric cytokine. IL-12 (cytotoxic lymphocyte maturation factor). Journal of Immunology, 147. 874-882.
18. h2 cell. European Journal of Immunology, 23, 1762-1770.
19. Kobayashi, M. Fitz, L., Ryan, M., Hewick, R.M., Clark, S.C., Chan, S., Loudon, R., Sherman, F., Perussia, B. & Trinchieri, G. (1989) Identification and purification of natural killer cell stimulatory factor (NKSF). a cytokine with multiple biologic effects on human lymphocytes. Journal of Experimental Medicine, 170, 827-845.
20. Lauria, F., Raspadori, D., Rondelli, D., Ventura, M.A. & Foa, R. (1994) In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia, 8, 724-728.
21. Lee, S.M., Suen, Y., Chang, L., Bruner, V., Qian, J., Indes, J., Knoppel, E., van de Ven. C. & Cairo, M.S. (1996) Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of Interferon-γ, natural killer, and lymphokine-activated killer activity by IL-12 in cord blood mononuclear cells. Blood, 88, 945-954.
22. Lim, S.H., Newland, A.C., Kelsey, S., Bell, A., Offermann, E., Rist, C., Gozzard, D., Bareford, D., Smith, M.P. & Goldstone, A.H. (1992) Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia: a phase II study. Cancer Immunology and Immunotherapy, 34, 337-342.
23. Lotzova, E., Savary, C.A., Keating, M.J. & Hester, J.P. (1985) Defective NK cell mechanism in patients with leukemia. Mechanisms for Cytotoxicity by NK Cells (ed. by R. B. Herberman and D. Callewaert). pp. 507-513. Academic Press, San Diego.
24. Manetti, R., Parronchi, P., Giudizi, M.E., Piccinni, M.P., Maggi, E., Trinchieri, G. & Romagnani, S. (1993) Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type I (ThI) specific immune responses and inhibits development of IL-4 producing Th cells. Journxal of Experimental Medicine, 177, 1199-1204.
25. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Gillio Tos, A. & Mandelli, F. (1994) Inlerleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood, 84, 2158-2163.
26. Nastala, C.L., Edington, H.D., McKinney, T.C., Tahara, H., Nalesnik, M.A., Brunda, M.J., Gately, M.K., Wolf, S.F., Schreiher, R.D., Storkus. W.J. & Lotze, M.T. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. Journal of Immunology, 153, 1697-1706.
27. Ogata, K., Tamura, H., Yokose, N., An, E., Dan, K., Hamaguchi, H., Sakamaki, H., Onozawa, Y., Clark, S.C. & Nomura, T. (1995) Effect of interleukin-12 on natural killer cell cytoloxicity and the production of interferon-γ and tumour necrosis factor-α in patients with myelodysplastic syndromes. British Journal of Haematology, 90, 15-21.
28. Oshimi, K., Oshimi, Y., Atmtsu, M., Takei, Y., Saito, H., Okada, M. & Mizogushi, H. (1986) Cytotoxicity of interleukin-2 activated lymphocytes for leukemia and lymphoma cells. Blood, 68, 938-948.
29. Rashleigh, S.P., Kusher, D.I., Endicott, J.N., Rossi, A.R. & Djeu, J.Y. (1996) Interleukins 2 and 12 activate natural killer cytolytic response of pheripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma. Archives of Otolaryngology: Head and Neck Surgery, 122, 541-547.
30. Robertson, M.J., Soffier, R.J., Wolf, S.F., Manley, T.J., Donahue, C., Young, D.H. & Ritz, J. (1992) Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. Journal of Experimental Medicine, 175, 779-788.
31. Rook, A.H., Kubin, M., Cassin, M., Vonderheid, E.C., Vowels, B.R., Wolfe, J.T., Wolf, S.F., Singh, A., Trinchieri, G. & Lessin, S.R. (1995) IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. Journal of Immunology, 154, 1491-1498.
32. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, J.T., Seipp, C.A., Simpson, C.G. & White, D.E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New England Journal of Medicine, 316, 889-897.
33. Rossi, A.R., Pericle, F., Rashleigh, S., Janiec, J. & Djeu, J.Y. (1994) Lysis of neuroblasloma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood, 83, 1323-1328.
34. Sarmiento, U.M., Riley, J.H., Knaack, P.A., Lipman, J.M., Becker, J.M. & Gately, M.K. (1994) Biologic effects of recombinant human interleukin-12 in squirrel monkey (Sciureus saimiri). Laboratory Investigation, 71, 862-875.
35. Soiffer, R.J., Murray, C., Cochran, K., Cameron, C., Wang. E., Schow, P.W., Daley, J.F. & Ritz, J. (1992) Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79, 517-526.
36. Soiffer, R.J., Robertson, M.J., Murray, C., Cochran, K. & Ritz, J. (1993) Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood, 82, 2790-2795.
37. Stern, A.S., Podlaski, F.J., Hulmes, J.D., Pan, Y.E., Quinn, P.M., Wolitzky, A.G., Familletti, P.C., Stremlo, D.L., Truitt, T., Chizzonite, R. & Gately, M.K. (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proceedings of the National Academy of Sciences of the United States of America, 87, 6808-6812.
38. Stern, A.S., Tarby, C.M., Tamborini, B. & Truitt, G.A. (1994) Preclinical development of IL-12 as an anticancer drug: comparison to IL-2. Proceedings of the American Association for Cancer Research, 35, 520 (abs. 3100).
39. Toze, C.L., Barnett, M.J. & Klingemann, H.G. (1993) Response of therapy-related myelodysplasia to low-dose interleukin-2. Leukemia, 7, 463-465.
40. Uharek, L., Zeis, M., Glass, B., Steinmann, J., Dreger, P., Gassman, W., Schmitz, N. & Müller-Ruchholtz, W (1996) High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL12 and IL2. Leukemia, 10, 1758-1764.
41. Verma, U.N. & Mazumder, A. (1995) Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points. Bone Marrow Transplantation, 16, 365-372.
42. West, W.H., Tauer, K.W., Yannelli, J.R., Marshall, G.D., Orr, D.W., Thurman, G.B. & Oldham, R.K. (1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New England Journal of Medicine, 316, 898-905.
43. Wigginton, J.M., Komschlies, K.L., Back, T.C., Franco, J.L., Brunda, M.J. & Wiltrout, R.H. (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. Journal of the National Cancer Institute, 88, 38-45.
44. Wolf, S.F., Temple, P.A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Hewick, R.M., Kelleher, K., Herrmann, S.H., Clark, S.C., Azzoni, L., Chan, S.H., Trinchieri, G. & Perussia, B. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of Immunology, 146, 3074-3081.
45. Wong, E.K., Eaves, C. & Klingemann, H.G. (1996) Comparison of natural killer activity of human bone marrow cells in cultures containing IL-2, IL-7 and IL-12. Bone Marrow Transplantation, 18, 63-71.